In-Vitro Diagnostics, Point of Care Testing & Pathology Services
SUPPLY CHAIN COORDINATION LIMITED
- Value
- £843,722,155
- Published
- 22 Oct 2026
- Deadline
- 16 Dec 2026
- Procedure
- Open procedure
- Category
- 85111800 — Pathology services; 33127000 — Immuno-analysis devices; 33124100 — Diagnostic devices; 33124130 — Diagnostic supplies; 33124131 — Reagent strips; 33140000 — Medical consumables; 33141500 — Haematological consumables; 33141625 — Diagnostic kits; 33186200 — Blood and fluid warming; 33192500 — Test tubes; 33696000 — Reagents and contrast media; 33696100 — Blood-grouping reagents
- Location
- UK, United Kingdom
- Notice reference
- 100209-2026
Requirements summary
Supply Chain Coordination Limited, on behalf of NHS Supply Chain, is running an open procedure to establish a national framework for in-vitro diagnostic devices, point-of-care testing (POCT) products and related pathology services. The notice lists three lots: Pathology Managed Services, Pathology Software Solutions, and Diagnostics Testing Solutions, with a contract period of 18 October 2027 to 17 October 2029 and a stated gross value of GBP 843,722,155. The notice text is truncated, so some details may be incomplete.
Key requirements
- National framework for in-vitro diagnostics, POCT products and related pathology services across NHS settings
- Pathology managed services covering preanalytical, analytical and postanalytical stages, including expansion into Community Diagnostic Centres
- Pathology software solutions for lab workflows, sample tracking and archiving, data interoperability, and integration with lab hardware
- Diagnostic testing solutions across all pathology disciplines, screening programmes, POCT, and home/self-testing pathways
- Supply of core laboratory equipment, instruments, reagents and consumables, plus reagent rental, maintenance, specimen collection and storage
- Contract period 18 October 2027 to 17 October 2029; tender submission due 16 December 2026
- Award weighting: non-financial technical quality up to 80% (Lot 1 and 2) or 60% (Lot 3), social value 10%, commercial 10% (Lots 1 and 2) or 30% (Lot 3); SME and VCSE suitability indicated